Metabolic and Oxidative Stress Management Heterogeneity in a Panel of Breast Cancer Cell Lines

• Published in: Metabolites 2024-08, Vol.14 (8), p.435
• Main Authors: Maycotte, Paola, Sarmiento-Salinas, Fabiola Lilí, García-Miranda, Alin, Ovando-Ovando, Cesar Ivan, Robledo-Cadena, Diana Xochiquetzal, Hernández-Esquivel, Luz, Jasso-Chávez, Ricardo, Marín-Hernández, Alvaro
• Format: Article
• Language: English
• Subjects: Antibodies; antioxidant system; Antioxidants; Biosynthesis; Biotechnology; Breast cancer; Cancer therapies; Cell death; Cell signaling; Cells; Cellular signal transduction; Dehydrogenases; Disease management; Energy metabolism; Enzymes; Estrogen receptors; Glucose metabolism; Glycolysis; Health aspects; Instrument industry; Insulin; Metabolism; Metabolites; Mitochondria; Oxidative metabolism; Oxidative stress; Penicillin; Physiological aspects; Protein turnover; Proteins; Reactive oxygen species; Tumor cell lines
• ISSN: 2218-1989; 2218-1989
• DOI: 10.3390/metabo14080435

Metabolic alterations are recognized as one of the hallmarks of cancer. Among these, alterations in mitochondrial function have been associated with an enhanced production of Reactive Oxygen Species (ROS), which activate ROS-regulated cancer cell signaling pathways. Breast cancer is the main cancer-related cause of death for women globally. It is a heterogeneous disease with subtypes characterized by specific molecular features and patient outcomes. With the purpose of identifying differences in energy metabolism and the oxidative stress management system in non-tumorigenic, estrogen receptor positive (ER+) and triple negative (TN) breast cancer cells, we evaluated ROS production, protein enzyme levels and activities and profiled energy metabolism. We found differences in energetic metabolism and ROS management systems between non-tumorigenic and cancer cells and between ER+ and TN breast cancer cells. Our results indicate a dependence on glycolysis despite different glycolytic ATP levels in all cancer cell lines tested. In addition, our data show that high levels of ROS in TN cells are a result of limited antioxidant capacity in the NADPH producing and GSH systems, mitochondrial dysfunction and non-mitochondrial ROS production, making them more sensitive to GSH synthesis inhibitors. Our data suggest that metabolic and antioxidant profiling of breast cancer will provide important targets for metabolic inhibitors or antioxidant treatments for breast cancer therapy.